Defence Therapeutics Inc. reports developments in biotechnology and precision intracellular drug delivery through its proprietary Accum® platform. Company news centers on cancer-therapy applications, including antibody-drug conjugates, radiopharmaceutical and radio-immunoconjugate programs, and other complex biologics designed for intracellular and nuclear delivery.
Recurring updates also cover scientific advisory activity, industry presentations, collaboration work such as its program with Canadian Nuclear Laboratories, partnership outreach, and capital-structure actions including private placements, warrant amendments, and restricted stock unit grants.
Defence Therapeutics (DTCFF) issued 320,000 common shares to convertible debenture holders to settle accrued and unpaid interest.
The shares satisfied $160,000 in interest on debentures dated September 15, 2025, with $2,000,000 in principal and an 8% annual interest rate. The interest shares carry a statutory hold period of four months plus one day.
Under its March 6, 2026 sharing agreement with Sorbie Bornholm LP, Defence received its third settlement of $190,670.42 on October 14, 2026, against 606,060 placement shares released to SBLP. As of October 23, 2026, 9,090,911 placement shares remained in escrow, with 15 settlement payments remaining.
Defence Therapeutics (DTCFF) won the Best Poster Award for its Accum research at World ADC San Diego 2026, held October 12–15. The poster, presented by senior scientist Dr. Guillaume Lefrançois, examined Accum as an intracellular drug-delivery platform for antibody-drug conjugates, or ADCs.
Defence also led an October 14 main-stage discussion on intracellular delivery, moderated by President and CEO Dr. Amie Phinney, with ADC industry experts participating. The company established new industry and academic contacts and said its goal is to translate scientific recognition and engagement into partnerships that advance Accum and create future licensing and commercial opportunities.
Defence Therapeutics (DTCFF) will participate in the 17th World ADC San Diego conference, taking place October 12–15, 2026, in San Diego.
President and CEO Dr. Amie Phinney will give a presentation and fireside discussion on October 14 at 12:30 p.m. about intracellular delivery, the movement of treatments within cells, in antibody-drug conjugates (ADCs). The session will introduce the scientific rationale behind Defence's Accum platform and explore potential applications. Senior Scientist Dr. Guillaume Lefrançois will present a poster during the Tuesday afternoon scientific session highlighting ongoing research evaluating Accum as an intracellular trafficking platform for ADCs.
Defence Therapeutics (DTCFF) appointed Sherry Aulin to its board of directors and audit committee.
Aulin has more than 20 years of experience with public companies and capital markets. She was most recently chief financial officer of Xenon Pharmaceuticals, where she served for over a decade and led financing activities that raised more than US$1 billion in equity capital. Defence granted her 400,000 stock options exercisable at 40 cents per share for five years. Of those, 200,000 vested immediately and 200,000 will vest on the first anniversary of the grant.
Defence Therapeutics (DTCFF) outlined a scientific advisory board change, executive stock awards and a sharing-agreement settlement. Its priorities include partnered Accum-enhanced antibody-drug conjugates, in-house radiotherapeutics and development options for AccuTOX.
Dr. Svetlana Selivanova resigned from the board to join its scientific advisory board. The board approved 7,000,000 restricted stock units for CEO Dr. Amie Phinney and Executive Chairman Sébastien Plouffe. They are issuable in five equal installments if the shares reach specified closing-price milestones and expire September 24, 2029.
Defence received a $249,696.72 second settlement on September 15 against 606,060 placement shares released to Sorbie Bornholm LP. Another 9,696,971 placement shares remain in escrow, with 16 settlement payments remaining.
Defence Therapeutics (DTCFF) released a CEO letter on September 8, 2026 outlining recent progress and strategic priorities.
New President and CEO Dr. Amie Phinney describes a sharpened focus on leveraging the proprietary Accum® drug-delivery platform in oncology. Following an earlier capital raise and additions to leadership, board, scientific staff and laboratory capabilities, the company plans to pursue growth through partnered programs and a focused internal pipeline. Development will concentrate on three areas: Accum®-enhanced antibody-drug conjugates (ADCs), Accum®-enabled radiotherapeutics, and defining the future of the clinical-stage AccuTOX® program.
The company is seeking revenue-generating ADC partnerships and licences, building a portfolio of Accum®-enabled radiotherapeutics toward clinical development, and undertaking a disciplined review of strategic options for AccuTOX®, including partnering, out-licensing or selective reactivation in melanoma.
Defence Therapeutics (DTCFF) updated investors on its March 6, 2026 Sharing Agreement with Sorbie Bornholm LP tied to a $6,000,000 subscription within a $9,595,000.25 private placement of 17,445,455 units at $0.55 per unit.
The Sharing Agreement provides for 18 monthly cash settlements benchmarked at $0.7332 per share, with each payment adjusted using a 20-day volume-weighted average price (20 Day VWAP) and a reference monthly amount of $333,333. If the 20 Day VWAP is below the benchmark, the Company receives less than $333,333; if above, it receives more. The Company has received the first Settlement of $182,623.49 as of August 14, 2026, against 606,060 Placement Shares released to SBLP. A remaining 10,303,031 Placement Shares are held in escrow, and 17 Settlement payments are still to be made.
Defence Therapeutics (OTCQB: DTCFF) announced an expansion of its radiopharmaceutical development strategy to evaluate both alpha-emitting and beta-emitting radioisotopes using its Accum® intracellular delivery platform. The initiative aims to broaden Accum®'s use in precision oncology by enhancing intracellular transport of radioactive payloads into cancer cells.
The program will study alpha emitters such as Actinium-225 and beta emitters such as Lutetium-177, generating comparative pharmacology, efficacy and safety data across both isotope classes. Ongoing preclinical work focuses on optimizing tumor cell accumulation, reducing off-target toxicity, and advancing Accum®-enabled radio-immunoconjugate candidates toward future clinical development.
Defence Therapeutics (OTCQB: DTCFF) appointed Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs, aiming to strengthen leadership as it advances its radiopharmaceutical drug conjugate (RDC) pipeline.
Dr. Simms has over 20 years of experience in targeted radiopharmaceuticals, including leadership roles at Fusion Pharmaceuticals, which was acquired by AstraZeneca in 2024 for approximately US$2 billion, as well as Abdera Therapeutics and the Centre for Probe Development and Commercialization. His background spans CMC strategy, manufacturing, isotope supply, radiochemistry and technical operations. Defence highlighted that his near-term focus will be selecting a lead RDC candidate, driving preclinical characterization, and establishing the CMC and manufacturing framework required to progress toward the clinic. The appointment follows the recent naming of Dr. Amie Phinney as President and CEO and the opening of a new office at McMaster Innovation Park in Hamilton.
Defence Therapeutics (CSE: DTC, OTCQB: DTCFF, FSE: DTC) appointed Dr. Amie Phinney as President and Chief Executive Officer, effective August 1, 2026, while founder Sébastien Plouffe became Executive Chairman, continuing to oversee strategy, financing, partnerships, and long-term growth.
Dr. Phinney joined Defence in 2025, serving as Strategy & Business Advisor and Board member, and brings over two decades of global experience across Abbott, AbbVie, Lakeside Discovery, adMare BioInnovations and Block Biosciences. Under her leadership, Defence plans to advance its Accum® intracellular drug-delivery platform across ADCs, radiotherapeutics and other targeted biologics, and expand strategic collaborations.
The company also granted 600,000 incentive stock options at an exercise price of $0.40 per share: 200,000 to Dr. Phinney (half vesting immediately, half after one year), 200,000 to an employee on the same terms, and 200,000 to the Executive Chairman, fully vested with a ten-year term.